Newsfeeds - Spark Newswire

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

Today, 10:29 AM

Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the press release, Q4 earnings came out 2 days ago.

ADGI

3 minute read

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

By Shanthi Rexaline

Today, 10:29 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ADAG

2 minute read

Analyst Ratings

Expert Ratings For Apellis Pharmaceuticals

By Benzinga Insights

Today, 10:29 AM

Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

APLS

1 minute read

Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $86

By Benzinga Newsdesk

Today, 10:29 AM

Goldman Sachs maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $102 to $86.

APLS

1 minute read

Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $114

By Benzinga Newsdesk

Today, 10:29 AM

Raymond James analyst Timur Ivannikov maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and raises the price target from $112 to $114.

APLS

1 minute read

Earnings

Apellis Pharmaceuticals: Q4 Earnings Insights

By Benzinga Insights

Today, 10:29 AM

Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

APLS

10 minute read

Earnings Scheduled For February 28, 2022

By Benzinga Insights

Today, 10:29 AM

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

AAON

1 minute read

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 10:29 AM

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:

APLS

1 minute read

Apellis – Sobi’s Pegcetacoplan Wins European Approval For Rare Blood Disorder

By Vandana Singh

Today, 10:29 AM

The European Commission has approved Swedish Orphan Biovitrum AB (OTC:BIOVF) – Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) Aspaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The…

APLS

3 minute read

FDA
News

Apellis And Sobi Say Empaveli Demonstrated Sustained Normalization Of Clinical Measures In Broad PNH Patient Population

By Benzinga Newsdesk

Today, 10:29 AM

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today new data demonstrating that Empaveli™/Aspaveli® (pegcetacoplan) providesApellis Pharmaceuticals, Inc.

APLS